Anne Haney Cross

Q: What Schools Are Affiliated With Anne Haney Cross

Anne Haney Cross is affiliated with the following schools: Harvard University, Washington University in St. Louis, University of Alabama, Johns Hopkins University

Anne Haney Cross's AcademicInfluence.com Rankings

Anne Haney Cross

Medical

#2496

World Rank

#2923

Historical Rank

#471

USA Rank

Neurology

#242

World Rank

#320

Historical Rank

#48

USA Rank

medical Degrees

Download Badge

Medical

Anne Haney Cross's Degrees

Doctorate Medicine Harvard University

Why Is Anne Haney Cross Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Anne Cross is an American neurologist and neuroimmunologist and the Section Head of Neuroimmunology at Washington University School of Medicine in St. Louis, Missouri. Cross holds the Manny and Rosalyn Rosenthal–Dr. John L. Trotter Endowed Chair in Neuroimmunology at WUSTL School of Medicine and co-directs the John L Trotter Multiple Sclerosis Clinic at Barnes-Jewish Hospital. Cross is a leader in the field of neuroimmunology and was the first to discover the role of B cells in the pathogenesis of multiple sclerosis in animals and then in humans. Cross now develops novel imaging techniques to observe inflammation and demyelination in the central nervous systems of MS patients for diagnosis and disease management.

(See a Problem?)

Anne Haney Cross's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis (2011) (2511)
Dysmyelination Revealed through MRI as Increased Radial (but Unchanged Axial) Diffusion of Water (2002) (2459)
Diffusion tensor imaging detects and differentiates axon and myelin degeneration in mouse optic nerve after retinal ischemia (2003) (1686)
Demyelination increases radial diffusivity in corpus callosum of mouse brain (2005) (1568)
Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci (2009) (799)
Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility (2019) (589)
Anti—tumor necrosis factor therapy abrogates autoimmune demyelination (1991) (447)
Axial Diffusivity Is the Primary Correlate of Axonal Injury in the Experimental Autoimmune Encephalomyelitis Spinal Cord: A Quantitative Pixelwise Analysis (2009) (446)
Noninvasive detection of cuprizone induced axonal damage and demyelination in the mouse corpus callosum (2006) (438)
Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients (2006) (423)
Aminoguanidine, an inhibitor of inducible nitric oxide synthase, ameliorates experimental autoimmune encephalomyelitis in SJL mice. (1994) (400)
Toward accurate diagnosis of white matter pathology using diffusion tensor imaging (2007) (393)
Radial diffusivity predicts demyelination in ex vivo multiple sclerosis spinal cords (2011) (331)
Quantification of increased cellularity during inflammatory demyelination. (2011) (311)
A Diet Mimicking Fasting Promotes Regeneration and Reduces Autoimmunity and Multiple Sclerosis Symptoms. (2016) (297)
B cells are critical to induction of experimental allergic encephalomyelitis by protein but not by a short encephalitogenic peptide (1999) (296)
Fatigue therapy in multiple sclerosis (1995) (275)
Homing to central nervous system vasculature by antigen-specific lymphocytes. I. Localization of 14C-labeled cells during acute, chronic, and relapsing experimental allergic encephalomyelitis. (1990) (263)
Homing to central nervous system vasculature by antigen-specific lymphocytes. II. Lymphocyte/endothelial cell adhesion during the initial stages of autoimmune demyelination. (1990) (262)
Intermittent Fasting Confers Protection in CNS Autoimmunity by Altering the Gut Microbiota. (2018) (260)
Blockade of TREM‐2 exacerbates experimental autoimmune encephalomyelitis (2007) (257)
B cells and antibodies in CNS demyelinating disease (2001) (251)
Detecting axon damage in spinal cord from a mouse model of multiple sclerosis (2006) (239)
Identification of soluble TREM-2 in the cerebrospinal fluid and its association with multiple sclerosis and CNS inflammation. (2008) (227)
Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis. (2010) (222)
Ofatumumab versus Teriflunomide in Multiple Sclerosis. (2020) (220)
Differential sensitivity of in vivo and ex vivo diffusion tensor imaging to evolving optic nerve injury in mice with retinal ischemia (2006) (213)
Evolving Wallerian degeneration after transient retinal ischemia in mice characterized by diffusion tensor imaging (2008) (209)
Chronic calorie restriction attenuates experimental autoimmune encephalomyelitis (2008) (201)
Rituximab add-on therapy for breakthrough relapsing multiple sclerosis (2010) (199)
Peroxynitrite formation within the central nervous system in active multiple sclerosis (1998) (198)
The relationship of sleep disturbances and fatigue in multiple sclerosis. (2004) (197)
Optical coherence tomography differs in neuromyelitis optica compared with multiple sclerosis (2009) (190)
TREM2 regulates microglial cell activation in response to demyelination in vivo (2015) (188)
Critical role of antigen‐specific antibody in experimental autoimmune encephalomyelitis induced by recombinant myelin oligodendrocyte glycoprotein (2002) (187)
Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis (2021) (185)
Pathological expression of CXCL12 at the blood-brain barrier correlates with severity of multiple sclerosis. (2008) (184)
Axonal injury detected by in vivo diffusion tensor imaging correlates with neurological disability in a mouse model of multiple sclerosis (2008) (182)
Upregulation and coexpression of adhesion molecules correlate with relapsing autoimmune demyelination in the central nervous system (1990) (177)
Long-term inhibition of murine experimental autoimmune encephalomyelitis using CTLA-4-Fc supports a key role for CD28 costimulation. (1995) (177)
Fas and Fas ligand enhance the pathogenesis of experimental allergic encephalomyelitis, but are not essential for immune privilege in the central nervous system. (1997) (169)
Evidence for the production of peroxynitrite in inflammatory CNS demyelination (1997) (168)
Experimental allergic encephalomyelitis in the rat is inhibited by aminoguanidine, an inhibitor of nitric oxide synthase (1996) (160)
Dual Role for Fas Ligand in the Initiation of and Recovery from Experimental Allergic Encephalomyelitis (1999) (159)
Rostrocaudal Analysis of Corpus Callosum Demyelination and Axon Damage Across Disease Stages Refines Diffusion Tensor Imaging Correlations With Pathological Features (2010) (156)
Nitric oxide localized to spinal cords of mice with experimental allergic encephalomyelitis: an electron paramagnetic resonance study (1993) (155)
The contemporary spectrum of multiple sclerosis misdiagnosis (2016) (152)
Adhesion-related molecules in the central nervous system. Upregulation correlates with inflammatory cell influx during relapsing experimental autoimmune encephalomyelitis. (1991) (137)
Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial (2016) (132)
Axonal dystrophy as a consequence of long-term demyelination. (1989) (132)
Established and novel disease‐modifying treatments in multiple sclerosis (2014) (130)
Differentiation and quantification of inflammation, demyelination and axon injury or loss in multiple sclerosis. (2015) (128)
Cell-based therapeutic strategies for multiple sclerosis (2017) (128)
Oligoclonal band number as a marker for prognosis in multiple sclerosis. (2001) (117)
Mediation of inflammation by encephalitogenic cells: interferon γ induction of nitric oxide synthase and cyclooxygenase 2 (1995) (117)
The Multiple Sclerosis Genomic Map: Role of peripheral immune cells and resident microglia in susceptibility (2017) (113)
Disability in optic neuritis correlates with diffusion tensor-derived directional diffusivities (2009) (110)
Multiple sclerosis susceptibility alleles in African Americans (2009) (109)
Comprehensive follow-up of the first genome-wide association study of multiple sclerosis identifies KIF21B and TMEM39A as susceptibility loci (2009) (107)
Enhanced sphingosine-1-phosphate receptor 2 expression underlies female CNS autoimmunity susceptibility. (2014) (107)
Development of reactivity to new myelin antigens during chronic relapsing autoimmune demyelination. (1993) (106)
Anti-adhesion molecule therapy in experimental autoimmune encephalomyelitis (1993) (105)
Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients (2016) (104)
Dimethyl fumarate-associated lymphopenia: Risk factors and clinical significance (2015) (103)
Selective vulnerability of cerebral white matter in a murine model of multiple sclerosis detected using diffusion tensor imaging (2007) (101)
Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk (2018) (98)
Decreased circulating miRNA levels in patients with primary progressive multiple sclerosis (2013) (97)
Assessing optic nerve pathology with diffusion MRI: from mouse to human (2008) (95)
Quantifying white matter tract diffusion parameters in the presence of increased extra-fiber cellularity and vasogenic edema (2014) (94)
Biophysical mechanisms of MRI signal frequency contrast in multiple sclerosis (2012) (94)
Effects of MS disease-modifying therapies on responses to vaccinations: A review. (2020) (92)
Inducible nitric oxide synthase gene expression and enzyme activity correlate with disease activity in murine experimental autoimmune encephalomyelitis (1996) (92)
CXCL13 is a biomarker of inflammation in multiple sclerosis, neuromyelitis optica, and other neurological conditions (2013) (86)
Lack of adiponectin leads to increased lymphocyte activation and increased disease severity in a mouse model of multiple sclerosis (2013) (83)
Association of neuromyelitis optica with severe and intractable pain. (2012) (83)
Acute and bilateral blindness due to optic neuropathy associated with copper deficiency. (2009) (81)
Adhesion molecules on endothelial cells in the central nervous system: an emerging area in the neuroimmunology of multiple sclerosis. (1990) (80)
Phenotype and prognosis in African-Americans with multiple sclerosis: a retrospective chart review (2006) (80)
Optical coherence tomography is less sensitive than visual evoked potentials in optic neuritis (2009) (79)
Regulation of experimental autoimmune encephalomyelitis with insulin-like growth factor (IGF-1) and IGF-1/IGF-binding protein-3 complex (IGF-1/IGFBP3). (1998) (76)
Oral administration of myelin basic protein is superior to myelin in suppressing established relapsing experimental autoimmune encephalomyelitis. (1999) (74)
Radial diffusivity in remote optic neuritis discriminates visual outcomes (2010) (73)
Rituximab Therapy Reduces Organ-Specific T Cell Responses and Ameliorates Experimental Autoimmune Encephalomyelitis (2011) (73)
Speaking out about gender imbalance in invited speakers improves diversity (2017) (73)
Improved in vivo diffusion tensor imaging of human cervical spinal cord (2013) (72)
Genetic variation in the IL7RA/IL7 pathway increases multiple sclerosis susceptibility (2010) (70)
Rapid onset Mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis (2003) (68)
Spinal cord tract diffusion tensor imaging reveals disability substrate in demyelinating disease (2013) (64)
Elevated CSF free kappa light chains correlate with disability prognosis in multiple sclerosis (2006) (63)
Increased diffusivity in acute multiple sclerosis lesions predicts risk of black hole (2010) (62)
Increased radial diffusivity in spinal cord lesions in neuromyelitis optica compared with multiple sclerosis (2012) (58)
On the role of physiological fluctuations in quantitative gradient echo MRI: implications for GEPCI, QSM, and SWI (2015) (56)
Misdiagnosis of multiple sclerosis (2018) (55)
Neurological and neuropathologic heterogeneity in two brothers with cobalamin C deficiency (2001) (54)
Role of Fas–FasL interactions in the pathogenesis and regulation of autoimmune demyelinating disease (1999) (54)
Comparative assessment of Yale Single Q uestion and Beck Depression Inventory Scale in screening for depression in multiple sclerosis (2003) (54)
Genetic risk variants in African Americans with multiple sclerosis (2013) (54)
Gradient Echo Plural Contrast Imaging — Signal model and derived contrasts: T2*, T1, Phase, SWI, T1f, FST2*and T2*-SWI (2012) (53)
Disease-Modifying Treatment in Progressive Multiple Sclerosis (2018) (51)
Nitric oxide synthase inhibitor, aminoguanidine, reduces inflammation and demyelination produced by Theiler's virus infection (1998) (50)
High risk of postpartum relapses in neuromyelitis optica spectrum disorder (2017) (49)
HPRT mutant T-cell lines from multiple sclerosis patients recognize myelin proteolipid protein peptides (1997) (49)
Limited sufficiency of antigen presentation by dendritic cells in models of central nervous system autoimmunity. (2011) (48)
Fas(t) track to apoptosis in MS (2000) (48)
Dimethyl fumarate associated lymphopenia in clinical practice (2015) (48)
Dimethyl fumarate induces changes in B- and T-lymphocyte function independent of the effects on absolute lymphocyte count (2018) (47)
Single-cell RNA-seq analysis of human CSF microglia and myeloid cells in neuroinflammation (2020) (46)
MS and the B cell controversy. (2011) (44)
Hypothesis: Antigen-specific T cells prime central nervous system endothelium for recruitment of nonspecific inflammatory cells to effect autoimmune demyelination (1991) (43)
The present efficacy of multiple sclerosis therapeutics (2009) (43)
Central nervous system endothelial cell-polymorphonuclear cell interactions during autoimmune demyelination. (1991) (43)
Rituximab combination therapy in relapsing multiple sclerosis (2012) (41)
Astrocytes and central nervous system endothelial cells do not express B7-1 (CD80) or B7-2 (CD86) immunoreactivity during experimental autoimmune encephalomyelitis (2000) (41)
Higher IgG index found in African Americans versus Caucasians with multiple sclerosis (2007) (41)
A catalyst of peroxynitrite decomposition inhibits murine experimental autoimmune encephalomyelitis (2000) (40)
A little stress is good: IFN-γ, demyelination, and multiple sclerosis (2007) (40)
Use of Vitamins and Dietary Supplements by Patients With Multiple Sclerosis: A Review (2018) (39)
Expression profiling identifies a molecular signature of reactive astrocytes stimulated by cyclic AMP or proinflammatory cytokines (2008) (39)
Adoptively transferred acute and chronic relapsing autoimmune encephalomyelitis in the PL/J mouse and observations on altered pathology by intercurrent virus infection. (1987) (38)
Regulatory T Cells Suppress the Late Phase of the Immune Response in Lymph Nodes through P-Selectin Glycoprotein Ligand-1 (2013) (38)
Relapsing autoimmune demyelination: a role for vascular addressins (1991) (37)
DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS OF MULTIPLE SCLEROSIS (2007) (37)
Effect of Multiple Sclerosis Disease-Modifying Therapies on B Cells and Humoral Immunity. (2016) (37)
Interleukin-10 Overexpression Promotes Fas-Ligand-Dependent Chronic Macrophage-Mediated Demyelinating Polyneuropathy (2009) (37)
Elevated intrathecal myelin oligodendrocyte glycoprotein antibodies in multiple sclerosis. (2010) (36)
“A new imaging modality to non-invasively assess multiple sclerosis pathology” (2017) (35)
Axonal transport rate decreased at the onset of optic neuritis in EAE mice (2014) (34)
Differential expression of suppressors of cytokine signaling-1 and -3 and related cytokines in central nervous system during remitting versus non-remitting forms of experimental autoimmune encephalomyelitis. (2006) (34)
Diffusion MRI quantifies early axonal loss in the presence of nerve swelling (2017) (34)
Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk (2018) (33)
In vivo quantitative evaluation of brain tissue damage in multiple sclerosis using gradient echo plural contrast imaging technique (2010) (33)
NMO-IgG DETECTED IN CSF IN SERONEGATIVE NEUROMYELITIS OPTICA (2009) (32)
T cells are the main cell type expressing B7‐1 and B7‐2 in the central nervous system during acute, relapsing and chronic experimental autoimmune encephalomyelitis (1999) (32)
Effects of dietary restriction on neuroinflammation in neurodegenerative diseases (2021) (31)
Spinal cord ring enhancement in multiple sclerosis. (2010) (31)
Phosphatidylserine, a putative inhibitor of tumor necrosis factor, prevents autoimmune demyelination (1993) (31)
Gradient echo magnetic resonance imaging correlates with clinical measures and allows visualization of veins within multiple sclerosis lesions (2014) (30)
Protein array–based profiling of CSF identifies RBPJ as an autoantigen in multiple sclerosis (2013) (30)
Postpartum cerebral vasospasm treated with hypervolemic therapy. (1996) (29)
On the relationship between cellular and hemodynamic properties of the human brain cortex throughout adult lifespan (2016) (29)
B cells limit epitope spreading and reduce severity of EAE induced with PLP peptide in BALB/c mice. (2008) (29)
An overview of the current state of evidence for the role of specific diets in multiple sclerosis. (2019) (28)
Neurologic manifestations of celiac disease (2003) (28)
A little stress is good: IFN-gamma, demyelination, and multiple sclerosis. (2007) (28)
Clinical and laboratory features distinguishing MOG antibody disease from multiple sclerosis and AQP4 antibody-positive neuromyelitis optica. (2020) (28)
Diffusion tensor imaging in acute optic neuropathies: predictor of clinical outcomes. (2012) (28)
Female hormonal exposures and neuromyelitis optica symptom onset in a multicenter study (2017) (28)
Deep learning with diffusion basis spectrum imaging for classification of multiple sclerosis lesions (2020) (27)
Murine encephalitogenic lymphoid cells induce nitric oxide synthase in primary astrocytes (1996) (27)
Predicting optimal response to B-cell depletion with rituximab in multiple sclerosis using CXCL13 index, magnetic resonance imaging and clinical measures (2015) (27)
Non-specific oligodendrocyte cytotoxicity mediated by soluble products of activated T cell lines (1991) (27)
Immune cell traffic control and the central nervous system (1992) (26)
Does the hepatitis B vaccine cause multiple sclerosis? (2004) (25)
Dysmyelinated axons in shiverer mice are highly vulnerable to α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor-mediated toxicity (2010) (24)
Cerebrospinal fluid progranulin levels in patients with different multiple sclerosis subtypes (2010) (24)
Alterations of host-gut microbiome interactions in multiple sclerosis (2022) (23)
Acute aphasia in multiple sclerosis. (2000) (23)
Identification of the encephalitogenic epitopes of CNS proteolipid protein in BALB/c mice. (2002) (22)
Multiple sclerosis and black holes: connecting the pixels. (2005) (22)
Apolipoprotein E mediation of neuro-inflammation in a murine model of multiple sclerosis (2014) (21)
Antibodies to beta-interferons in multiple sclerosis (1998) (21)
Detection and quantification of regional cortical gray matter damage in multiple sclerosis utilizing gradient echo MRI (2015) (21)
Diffusion basis spectrum imaging provides insights into MS pathology (2019) (20)
Adoptive transfer of experimental allergic encephalomyelitis and localization of the encephalitogenic epitope in the SWR mouse (1991) (20)
Alterations of the gut mycobiome in patients with MS (2021) (20)
Humoral immunity in multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis (2005) (20)
B cells: No longer the nondominant arm of multiple sclerosis (2007) (20)
Interferon-gamma produced by encephalitogenic cells induces suppressors of cytokine signaling in primary murine astrocytes (2004) (19)
Can CSF biomarkers predict future MS disease activity and severity? (2020) (18)
Antigen processing of myelin basic protein is required prior to recognition by T cells inducing EAE. (1990) (18)
ITAM signaling in dendritic cells controls T helper cell priming by regulating MHC class II recycling. (2010) (17)
Diffusion fMRI detects white-matter dysfunction in mice with acute optic neuritis (2014) (17)
Efficacy and tolerability of oral versus injectable disease-modifying therapies for multiple sclerosis in clinical practice (2016) (16)
Interferon beta use and disability prevention in relapsing-remitting multiple sclerosis. (2013) (16)
Anti-CD20 B Cell Treatment for Relapsing Multiple Sclerosis (2021) (16)
Multiple sclerosis: Oligoclonal bands still yield clues about multiple sclerosis (2010) (15)
Histopathological correlation of diffusion basis spectrum imaging metrics of a biopsy-proven inflammatory demyelinating brain lesion: A brief report (2018) (15)
Interleukin‐2 binding proteins in sera from normal subjects and multiple sclerosis patients (1995) (14)
MS: The return of the B cell (2000) (14)
CTLA-4-Fc treatment of ongoing EAE improves recovery, but has no effect upon relapse rate. Implications for the mechanisms involved in disease perpetuation (1999) (14)
Measurement of upregulation of inducible nitric oxide synthase in the experimental autoimmune encephalomyelitis model using a positron emitting radiopharmaceutical. (1997) (13)
NOS2 regulates cytokine production and VLA-4 expression in experimental autoimmune encephalomyelitis (2006) (13)
Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk (2020) (13)
COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab (2022) (12)
Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years (2022) (12)
Serial adoptive transfer of murine experimental allergic encephalomyelitis: successful transfer is dependent on active disease in the donor (1990) (12)
Single scan quantitative gradient recalled echo MRI for evaluation of tissue damage in lesions and normal appearing gray and white matter in multiple sclerosis (2018) (12)
Update on multiple sclerosis, its diagnosis and treatments (2012) (11)
Central vein sign and other radiographic features distinguishing myelin oligodendrocyte glycoprotein antibody disease from multiple sclerosis and aquaporin-4 antibody-positive neuromyelitis optica (2021) (11)
Association of Chlamydia pneumoniae and multiple sclerosis: Stage two? (2001) (11)
T cells producing GM-CSF and IL-13 are enriched in the cerebrospinal fluid of relapsing MS patients (2020) (11)
Limbic system damage in MS: MRI assessment and correlations with clinical testing (2017) (11)
Intensity ratio to improve black hole assessment in multiple sclerosis. (2018) (11)
Diffusion basis spectrum imaging for identifying pathologies in MS subtypes (2019) (11)
Effectiveness of alternative dose fingolimod for multiple sclerosis (2018) (11)
Lack of response to monoclonal antibody therapy in neuromyelitis optica. (2011) (10)
COVID-19 in Patients With Neuromyelitis Optica Spectrum Disorders and Myelin Oligodendrocyte Glycoprotein Antibody Disease in North America (2021) (10)
Candidate gene analysis of selectin cluster in patients with multiple sclerosis (2009) (9)
Streamlined EDSS for use in multiple sclerosis clinical practice: Development and cross-sectional comparison to EDSS (2018) (9)
Simultaneous multi‐angular relaxometry of tissue with MRI (SMART MRI): Theoretical background and proof of concept (2017) (8)
Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II (2022) (8)
Towards Accurate In Vivo Diffusion Measurement in Human Optic Nerve (2007) (8)
B Cells, T Cells and Inflammatory CSF Biomarkers in Primary Progressive MS and Relapsing MS in the OBOE (Ocrelizumab Biomarker Outcome Evaluation) Trial (1635) (2020) (7)
Monoclonal Antibodies as Disease Modifying Therapy in Multiple Sclerosis (2013) (7)
CD11c+CD88+CD317+ myeloid cells are critical mediators of persistent CNS autoimmunity (2020) (7)
MS and related disorders: groundbreaking news (2014) (6)
Ofatumumab versus teriflunomide in relapsing MS: adaptive design of two Phase 3 studies (ASCLEPIOS I and ASCLEPIOS II) (S16.005) (2017) (6)
In vivo evolution of biopsy‐proven inflammatory demyelination quantified by R2t* mapping (2020) (6)
Detection of cortical lesions in multiple sclerosis: A new imaging approach (2015) (6)
Interim Analysis of the OBOE (Ocrelizumab Biomarker Outcome Evaluation) Study in Multiple Sclerosis (MS) (S24.002) (2018) (6)
In Vitro and In Vivo Investigation of S1PR1 Expression in the Central Nervous System Using [3H]CS1P1 and [11C]CS1P1. (2021) (6)
Regulation of experimental autoimmune encephalomyelitis with insulin-like growth factor (IGF-1) and IGF-1/IGF binding protein-3 complex (1998) (5)
The spectrum of multiple sclerosis misdiagnosis in the era of McDonald criteria: A multicenter study (PL01.003) (2016) (5)
A Novel Gradient Echo Plural Contrast Imaging Method Detects Brain Tissue Abnormalities in Patients With TBI Without Evident Anatomical Changes on Clinical MRI: A Pilot Study. (2019) (5)
Multiple encephalitogenic peptides of myelin basic protein in A.CA mice. (1993) (5)
Clinical instrument to retrospectively capture levels of EDSS. (2019) (5)
McAlpine's multiple sclerosis 2nd edn., W.B. Matthews, A. Compston, I.V. Allen and C.N. Martyn (Eds.), Churchill Livingstone, New York, 1991, 401 pp., $89.95 (1991) (4)
Quantitative signal properties from standardized MRIs correlate with multiple sclerosis disability (2021) (4)
A case of oligodendroglioma and multiple sclerosis: Occam’s razor or Hickam’s dictum? (2018) (4)
A Combination Trial of Estriol Plus Glatimer Acetate in Relapsing-Remitting Multiple Sclerosis (I7-2.002) (2014) (4)
The four seasons of multiple sclerosis (2010) (4)
The association between handedness and clinicodemographic characteristics in people with multiple sclerosis: a brief report (2019) (4)
Refining the use of MRI to predict multiple sclerosis (2017) (4)
Tissue damage detected by quantitative gradient echo MRI correlates with clinical progression in non-relapsing progressive MS (2021) (4)
Acute visual function impairment in EAE is primarily caused by optic nerve inflammation as assessed by DBSI (2011) (4)
Active and progressive (2014) (3)
Diffusion Tensor Imaging in Acute Optic Neuropathies (2016) (3)
Autoantibodies in Demyelinating Disease (2001) (3)
MINI-review of Epstein-Barr virus involvement in multiple sclerosis etiology and pathogenesis (2022) (3)
Prognostic Value of Serum Neurofilament Light Chain for Disease Activity and Worsening in Patients With Relapsing Multiple Sclerosis: Results From the Phase 3 ASCLEPIOS I and II Trials (2022) (3)
Axonal injury detected by in vivo DTI correlates with neurological disability in a mouse model of Multiple Sclerosis (2008) (3)
Charting a global research strategy for progressive MS—An international progressive MS Alliance proposal (2021) (3)
Autoimmune demyelination in transgenic E alpha d-positive A.CA mice. Comparison with E-negative A.CA mice. (1992) (3)
Antibodies to potassium channels in multiple sclerosis. (2012) (2)
Diffusion Histology Imaging to Improve Lesion Detection and Classification in Multiple Sclerosis (2019) (2)
T cell autoimmunity in the central nervous system--a new twist at an old rope. (1990) (2)
Differential effects of anti-CD20 therapy on CD4 and CD8 T cells and implication of CD20-expressing CD8 T cells in MS disease activity (2023) (2)
Toward Reproducible Tract-specific In Vivo Diffusion Quantification in Human Cervical Spinal Cord (2009) (2)
Diffusion basis spectrum imaging measures anti-inflammatory and neuroprotective effects of fingolimod on murine optic neuritis (2021) (2)
Comment: Assessing humoral immunocompetence after alemtuzumab treatment in MS (2013) (2)
CTLA4-Ig treatment prevents murine experimental autoimmune encephalomyelitis (1994) (2)
Caveat regarding immunoglobulin therapy in multiple sclerosis (1993) (2)
Amelioration of EAE by a cryptic epitope of myelin oligodendrocyte glycoprotein (2016) (2)
Rituximab treatment reduces organ-specific T cell effector responses and ameliorates Experimental Autoimmune Encephalomyelitis (107.3) (2011) (1)
Advantages of Gradient Echo Plural Contrast Imaging for Identifying MS Abnormalities in Postmortem Brain Tissue (2008) (1)
Regulatory T cells session 1(WS-045a) Chairpersons: Sayuri Yamazaki, Steven Ziegler (2010) (1)
The CELLO trial: Protocol of a planned phase 4 study to assess the efficacy of Ocrelizumab in patients with radiologically isolated syndrome. (2022) (1)
High Risk of Initial Symptom Onset Post-Partum in Neuromyelitis Optica (S60.001) (2013) (1)
In-vivo Quantitative Measure of Black Hole Severity in Multiple Sclerosis with Gradient Echo Plural Contrast Imaging (2008) (1)
Progranulin genetic variability in primary progressive multiple sclerosis (2009) (1)
Enhancing our understanding of white matter changes in early multiple sclerosis. (2015) (1)
IVth Congress of the International Society of Neuroimmunology Amsterdam, the Netherlands, 23–27 October 1994 (1995) (1)
Directional diffusivity as a magnetic resonance (MR) biomarker in demyelinating disease (2007) (1)
Anti-tumor necrosis factor (anti-TNF) therapy abrogates autoimmune demyelination: New therapeutic implications for multiple sclerosis (1991) (1)
Co-expression of adhesion molecules during GNS inflammation in murine EAE (1991) (1)
Diffusion Basis Spectrum Imaging Detects Axonal Loss After Transient Dexamethasone Treatment in Optic Neuritis Mice (2021) (1)
MS can be considered a primary progressive disease in all cases, but some patients have superimposed relapses – No (2021) (1)
B-cell Depletion and Efficacy Outcomes with Ofatumumab: Subgroup Analysis From the Pooled Phase 3 ASCLEPIOS I and II Trials (2356) (2020) (1)
Correction to: COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab (2022) (1)
Confirming a Historical Diagnosis of Multiple Sclerosis: Challenges and Recommendations. (2022) (1)
Diffusion MRI quantifies early axonal loss in the presence of nerve swelling (2017) (0)
TNF-{alpha} promotes CD4 T cell infiltration of the central nervous system (CNS) by altering the polarity of CXCL12 expression at the blood-brain barrier (BBB) (2007) (0)
Noninvasive Detection and Differentiation of Axonal Injury/Loss, Demyelination, and Inflammation (2014) (0)
JAMA Neurology Peer Reviewers in 2017. (2018) (0)
Immune Response Following COVID-19 Vaccination (mRNA or Non-mRNA) in Patients with Relapsing Multiple Sclerosis Treated with the Bruton’s Tyrosine Kinase Inhibitor Evobrutinib: An Update (P2-3.017) (2023) (0)
MAGNETIC RESONANCE IMAGING OF MULTIPLE SCLEROSIS (2007) (0)
Superior to Myelin in Suppressing Oral Administration of Myelin Basic Protein (1999) (0)
Evaluating brain damage in multiple sclerosis with simultaneous multi‐angular‐relaxometry of tissue (2022) (0)
Diffusion MRI derived immunohistochemistry equivalent “ stains ” of white matter pathology (2012) (0)
Schwann Cell Remyelination in the Multiple Sclerosis Central Nervous System. (2023) (0)
MSJ852092_supplementary_material – Supplemental material for T cells producing GM-CSF and IL-13 are enriched in the cerebrospinal fluid of relapsing MS patients (2019) (0)
Immunopathogenesis of Multiple Sclerosis (2014) (0)
COVID-19 in the pregnant or postpartum MS patient: Symptoms and outcomes (2022) (0)
A Diet Mimicking Fasting P romotes Regeneration and Reduces Autoimmunity and Multiple Sclerosis Symptoms Graphical (2016) (0)
Waubant, et al Neurology 2012 (2015) (0)
Quantitative MRI identifies lesional and non-lesional abnormalities in MOGAD. (2023) (0)
MiR-223 regulates myeloid derived suppressor cells during experimental autoimmune encephalomyelitis (2014) (0)
Diffusion Basis Spectrum Imaging Accurately Reflects Underlying Pathologies in Multiple Sclerosis Lesions Missed by Conventional MRI and DTI (2012) (0)
Modified EDSS for Use in Multiple Sclerosis Clinical Practice (P2.133) (2016) (0)
Endothelial Cells and Adhesion Molecules in Experimental Autoimmune Encephalomyelitis (2005) (0)
FATIGUE IN MS. AUTHOR'S REPLY (1996) (0)
A catalyst of peroxynitrite decomposition inhibits EAE, indicating a key role for peroxynitrite in CNS inflammatory demyelination (1998) (0)
John L. Trotter, MD (1943–2001) (2001) (0)
Expression of T cell co-stimulatory molecules within the CNS in inflammatory demyelination (1998) (0)
JAMA Neurology Peer Reviewers in 2017. (2018) (0)
Noninvasively Detection of the Pathological Changes of MS Lesions Responding to Treatment using Diffusion Basis Spectrum Imaging (2012) (0)
IMAGING IN MS RELATIVE CLINICAL UTILITY OF QUANTITATIVE MRI MEASURES IN THE SPINAL CORD IN MS PATIENTS (2013) (0)
Lymphocyte/vasculature interactions underlying formation of autoimmune demyelinating lesions (1991) (0)
UP-REGULATION BY CYTOKINES OF CLASS II MHC EXPRESSION ON GLIAL CELLS IN ORGANOTYPIC CNS CULTURES: 70 (1989) (0)
Stronger Microstructural Damage Revealed in Multiple Sclerosis Lesions With Central Vein Sign by Quantitative Gradient Echo MRI (2021) (0)
Expression of a membrane-bound and solubile form of TREM-2 in the central nervous system: association with multiple sclerosis (2007) (0)
Reduced Diffusion Encoding for Accurately Estimating Axonal Injury , Demyelination , and Inflammation in Mouse Optic Nerve (2012) (0)
Leveraging COViMS Registry to Understand the Impact of COVID-19 on Multiple Sclerosis (2020) (0)
Further support for rituximab in relapsing multiple sclerosis (2022) (0)
Dimethyl Fumarate Associated Lymphopenia in Clinical Practice (P3.240) (2015) (0)
2.11 Update on multiple sclerosis (2012) (0)
regulating MHC class II recycling ITAM signaling in dendritic cells controls T helper cell priming by (2014) (0)
Multiple sclerosis: Current treatment and future therapeutic directions (2001) (0)
SERIAL TRANSFER OF 14C-LABELED LYMPHOCYTES IN ADOPTIVELY TRANSFERRED EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS (EAE): 64 (1989) (0)
The oral administration of myelin basic protein (MBP) but not myelin suppresses chronic relapsing experimental autoimmune encephalomyelitis (EAE) (1998) (0)
ADOPTIVELY-TRANSFERRED CHRONIC RELAPSING EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS (EAE) IN THE PL/J MOUSE (1986) (0)
Tractography with Physiology Rendering of Human Brain using Diffusion Basis Spectrum Imaging (2012) (0)
MYELIN BASIC PROTEIN (MBP)-SPECIFIC T-CELLS ARE CYTOTOXIC FOR OLIGODENDROCYTES: 66 (1989) (0)
AXONAL ATTRITION IN DEMYELINATED PLAQUES: 67 (1989) (0)
Ring-Enhancing Lesions in MS: Longitudinal Quantification by Diffusion Tensor and Magnetization Transfer Imaging (P03.039) (2012) (0)
TNF-α promotes CD4 T cell infiltration of the central nervous system (CNS) by altering the polarity of CXCL12 expression at the blood-brain barrier (BBB) (96.18) (2007) (0)
Effects of Ocrelizumab on Neurofilament Light Chain and Other Biomarkers of Neuroinflammation and Neurodegeneration in MS: OBOE Study Design (P6.337) (2017) (0)
Antibody-mediated regulation of the response to a protective cryptic epitope in rMOG-induced EAE (BA8P.166) (2015) (0)
Diffusion fMRI of mouse optic nerve with antidromic electrical stimulation (2017) (0)
The North American Registry for Care and Research in Multiple Sclerosis (P2.398) (2018) (0)
Pain in Neuromyelitis Optica Is More Common, Disabling, and Refractory Compared to MS (P07.070) (2012) (0)
Selectin gene cluster genetic variation: association study in two independent multiple sclerosis populations. (2008) (0)
Antisense therapy (2014) (0)
"Brain age" predicts disability accumulation in multiple sclerosis. (2023) (0)
CHRONOLOGIC EXPRESSION OF ADHESION MARKERS IN THE CNS DURING ADOPTIVELY-TRANSFERRED EAE: 78 (1990) (0)
Notch: a mastermind of vascular morphogenesis (2007) (0)
Key role of TREM-2 on microglia in cuprizone-induced demyelination model (2014) (0)
Baseline Characteristics of Patients with Relapsing Multiple Sclerosis in ASCLEPIOS Phase 3 Trials of Ofatumumab Versus Teriflunomide (P3.2-096) (2019) (0)
Dual role for FAS (CD95) and FAS ligand (CD95L) in the initiation of and recovery from experimental allergic encephalomyelitis (1998) (0)
Phosphatidylserine-induced inhibition of experimental auto-immune encephalomyelitis (EAE) in mice (1991) (0)
Primary Central Nervous System Lymphoma Mimicking Multiple Sclerosis With Spontaneously Remitting Lesions (P5.172) (2014) (0)
Hormonal Exposures Relate to Clinical Phenotype in Women with Neuromyelitis Optica (S12.005) (2016) (0)
LYMPHOCYTE/ENDOTHELIAL CELL INTERACTIONS DURING INITIAL STAGES OF EXPERIMENTAL AUTOIMMUNE ENCEFHALOMYELITIS (EAE): 80 (1990) (0)
Autoimmune Encephalomyelitis Established Relapsing Experimental Is Superior to Myelin in Suppressing Oral Administration of Myelin Basic Protein (1999) (0)
Noninvasive Detection of Selective Vulnerability of Cerebral White Matter Tracts to Cuprizone (2008) (0)
Landmark papers in multiple sclerosis. (2001) (0)
Increased frequency of recognition of delipidated versus intact CNS myelin in multiple sclerosis and control subjects (1999) (0)
Myelin oligodendrocyte glycoprotein (MOG)peptide-induced EAE in B cell deficient C57BL/6 mice (1998) (0)
Immunology of Multiple Sclerosis (2021) (0)
Treatment of multiple sclerosis. Trial design, results and future perspectives Richard A. Rudick and Donald E. Goodkin (Eds.), Springer-Verlag, London, New York, 1992, 313 pp., $139.00. (1992) (0)
Regulation of eae using the growth factors TGF-β and IGF-1. MK (1996) (0)
HIGH ENDOTHELIAL VENULE ANTIGEN EXPRESSION IN MULTIPLE SCLEROSIS LESIONS: 82 (1990) (0)
Quantifying Axonal Injury , Demylination , and inflammation in Human MS Autopsy Specimens using Diffusion Basis Spectrum Imaging ( DBSI ) (2011) (0)

This paper list is powered by the following services:

Other Resources About Anne Haney Cross

en.wikipedia.org

What Schools Are Affiliated With Anne Haney Cross?

Anne Haney Cross is affiliated with the following schools:

Anne Haney Cross's Academic­Influence.com Rankings